ATTR-CM approved treatments

Overview

Approved therapies for people with transthyretin amyloid cardiomyopathy (ATTR-CM) target the underlying cause of the disease, helping to manage symptoms, slow disease progression, prevent complications and hospitalizations, and improve quality of life. These disease-modifying therapies work by suppressing the formation of the toxic transthyretin (TTR) protein clumps that drive this progressive heart disease, either by lowering TTR production or stabilizing the protein.

Amvuttra

Amvuttra (vutrisiran) is a TTR-lowering treatment approved for adults with ATTR-CM. It is administered via a subcutaneous, or under-the-skin, injection, once every three months.

Learn more

Attruby

Attruby (acoramidis) is an oral TTR stabilizer therapy approved for adults with ATTR-CM. Sold as Beyonttra in Europe, it is taken twice daily as oral tablets.

Learn more